Anson high teacher pays out of pocket to keep science exciting
Elizabeth Meyer, a science teacher at Anson High School, hosts one lab experiment per week, which she says can be a large amount of effort.
'Some people think me doing a lab every week is kind of crazy, and it's a lot of work, but I know the kids enjoy it. They get a lot out of it. They usually retain the material better. They do better on their test, and they get more interested in their class,' Meyer said.
'A colossal mistake': Abilene ISD superintendent criticizes Texas' new education voucher law
Shaking up fresh ice cream to exploding gummy bears, Meyer said the hands-on learning experience not only makes the classroom fun for students but also connects them to the material they are learning in class.
'I don't like just sitting there. Even in college, I doodled or messed with something, and so having hands-on experience really helps my kids get involved. They're engaged; they're doing what they're supposed to do. When somebody comes in, they like building roller coasters and catapults,' Meyer said.
With approximately 60 students and 36 weeks in a school year, 36 labs, the cost of materials can be pretty expensive, with Meyer having to come out of pocket most of the time.
'There's one lab that would be amazing to do, but it would cost so much to do. It. We just don't. So I try to find other things that the kids can do that show them the same thing. That's just a little simpler model,' Meyer said. 'I paid $100 at the grocery store just to do [an ice cream experiment with 10 students], so imagine doing one every week. And there are 36 weeks in a school year.'
Dan Patrick on THC ban, school choice + more in Abilene
Anson High School Principal, Gina Overby, said teachers buying their supplies is not uncommon for educators, especially those going above and beyond for their students.
'It makes me so happy to see that our teachers are willing to put our kids first, and not that we want them to go broke doing it, but at the same time, the fact that they're willing to shows to me how much our kids mean to our teachers,' Overby said.
Even with the cost burden, Meyer said she will not stop the labs, seeing the positive impact on her students.
'I had one student, and she literally did not want to come to school. She didn't like coming to school at all. One day, on the last day of school, she goes, 'You're probably the only reason I came to school.' That made me feel pretty good because you don't usually hear those comments from the kids,' Meyer explained.
'Don't forget to hug your momma': Big Country's Class of 2025 walks into the future
The school is accepting donations for science labs. They can be dropped off at Anson High School.
Here is a list of some of the previous materials the class has used:
Marbles
Pennies
Eggs
Popsicle Sticks
Mirrors
60 mL syringes
Light diodes
Bleach
Tent Stakes
Nylon Rope
Ammonia
Copper wire tape
3V Coin Batteries
Glass bottles
Soda cans
Rubberbands
Plastic Bags
String
Tape
Cups
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Epoch Times
3 days ago
- Epoch Times
Study Finds Elevated Liver Enzymes in Healthy Adults Using Cannabidiol
Healthy adults who took doses representative of consumer use of cannabidiol (CBD) daily for four weeks showed significant increases in liver enzymes—though no actual liver damage—in the first controlled trial to examine the cannabis compound's effects on liver function, researchers reported in JAMA Internal Medicine. CBD is a common chemical compound found in the cannabis plant, specifically in both hemp and marijuana. Unlike tetrahydrocannabinol (THC), another common cannabinoid, CBD does not produce a psychoactive effect, also called the 'high.'


New York Post
21-07-2025
- New York Post
Weed can help your migraines, says new study — if you use it the right way
High hopes for headache relief. A landmark new study suggests that inhaling a precise blend of CBD and THC can provide fast, meaningful relief from migraines. The research — presented at the American Headache Society (AHS) Annual Meeting 2025 — is the first of its kind. 4 The research — presented at the American Headache Society (AHS) Annual Meeting 2025 — is the first of its kind. Kateryna – 'This is the first placebo-controlled study in this space,' Dr. Nathaniel M. Schuster, a pain and headache neurologist and associate professor of anesthesiology at the UC San Diego (UCSD) Health Center for Pain Medicine, told Medscape Medical News. 'It's the first real — to me — compelling evidence for the antimigraine effects of cannabis in humans.' Scientists provided 92 patients — mostly women, with an average age of 41 — a treatment of 6% THC, 11% CBD, a combination of 6% THC and 11% CBD or a placebo. Roughly 67.2% in the THC/CBD group reported pain relief at 2 hours, compared to 46.6% in the placebo group. And approximately 34.5% of patients in the THC/CBD group achieved 'pain freedom' within that timeframe, compared to 15.5% in the placebo group. Patients also reported sustained pain relief up to 24 hours and most bothersome symptom freedom lasted through 48 hours. 4 'It's the first real — to me — compelling evidence for the antimigraine effects of cannabis in humans,' Schuster said. ststoev – Best of all: there were no serious side effects, although people in the THC-only group definitely got a little more high. 'It's known that CBD is a noncompetitive, negative allosteric modulator of the CB-1 [cannabinoid receptor 1] receptor that decreases the psychoactive side effects of the THC,' Schuster said. It's a big win for weed but, before you get rolling, Schuster noted that the patients received very controlled doses. 'A lot of neurologists, myself included, suspect that there could be medication overuse headache with [using] cannabinoids frequently,' he said. 'When I counsel patients now, I say, 'Look, we were only studying infrequent — four times over the course of a year — administration.'' 4 'A lot of neurologists, myself included, suspect that there could be medication overuse headache with [using] cannabinoids frequently,' he said. Africa Studio – He encouraged patients to limit the treatment to under 10 times per month and to 'optimally be using it really for those migraines that would not respond to standard-of-care therapy.' Weed has skyrocketed in popularity since 38 states and DC have legalized it for medical use. Of those, 24 states and DC have also cleared the way for adults 21 and over to use it recreationally. Research suggests that marijuana has the potential to ease chronic pain and reduce muscle spasms and stiffness linked to MS. Cannabis products have also been shown to boost appetite in HIV/AIDS and cancer patients, and combat chemo-related nausea. 4 Weed has skyrocketed in popularity since 38 states and DC have legalized it for medical use. Of those, 24 states and DC have also cleared the way for adults 21 and over to use it recreationally. amenic181 – Other potential benefits include easing stress, alleviating PTSD symptoms and aiding sleep in some people. However, mounting evidence does suggest it can pose risks to your heart, with one recent study showing marijuana has as much of a negative impact on cardiovascular health as tobacco — even if you don't smoke. Another recent study suggests that cannabis use raises the risk of heart attack and stroke more than cocaine, while other research claims it's sending older people to the hospital. Shockingly, scientists have also found that people with cannabis use disorder — that is, using weed enough that it causes problems and impairs your life — have altered dopamine activity in the brain that closely resembles patterns observed in psychosis. 'The biggest problem is that ever since it was made a Schedule 1 narcotic [in 1970], it has made it very difficult to do really well-devised, double-blind, placebo-controlled studies,' Dr. Ken Weinberg, chief medical officer of Cannabis Doctors of New York, previously told The Post. 'I don't think there's enough data.'


Miami Herald
03-07-2025
- Miami Herald
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects. "These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential," said Erez Aminov, Chairman and CEO of MIRA. "We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain." Study Overview and Key Findings Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume. Key findings: Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline analgesic effect was equivalent to morphine, the standard opioid comparator in the sedation or inflammatory swelling was observed with Mira-55 treatment. Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development. These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile. "Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards." Strategic Fit Within MIRA's Pain Portfolio Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain. "With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated," added Aminov. "We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline." Corporate Update on SKNY Merger MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction. "We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth." Next Steps MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones. About MIRA Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals